Welcome to the July edition of Tablets, a prescribing newsletter produced monthly by the Medicines Management team at Midlands and Lancashire Commissioning Support Unit.
BLACK CONJUGATED OESTROGENS and BAZEDOXIFENE ACETATE tablets (Duavive®)
The Pan Mersey Area Prescribing Committee does not recommend the prescribing of CONJUGATED OESTROGENS and BAZEDOXIFENE 0.45mg/20mg modified release tablets (Duavive®)for the treatment of oestrogen deficiency in postmenopausal women with a uterus. Tell me more about Duavive
BLACK RASBURICASE powder and solvent for concentrate for solution for infusion (Fasturtec®▼)for severe, refractory, tophaceous gout
The Pan Mersey Area Prescribing Committee does not recommend the prescribing of Rasburicase powder and solvent for concentrate for solution for infusion (Fasturtec®▼)for the "off label" treatment of severe, refractory, tophaceous gout resistant to xanthine oxidase inhibitors (allopurinol and febuxostat)and uricosuric agents (benzbromarone)or for whom these drugs are contraindicated. Tell me more about Rasburicase
BLACK THYROID EXTRACTS, DESICCATED
The Pan Mersey Area Prescribing Committee does not recommend the prescribing of DESICCATED THYROID EXTRACTS, e.g. Armour Thyroid, in the management of hypothyroidism. Tell me more about thyroid extracts
RED CERTOLIZUMAB PEGOL and SECUKINUMAB (Cimzia® and Cosentyx®▼ in Psoriatic Arthritis)
The Pan Mersey Area Prescribing Committee recommends the prescribing of CERTOLIZUMAB PEGOL (Cimzia®)and SECUKINUMAB (Cosentyx®▼), by specialists only, for psoriatic arthritis in accordance with NICE TA445. Tell me more about certolizumab and secukinumab
GREY INSULIN GLARGINE + LIXISENATIDE solution for injection (Suliqua®▼)
The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of INSULIN GLARGINE + LIXISENATIDE solution for injection (Suliqua®▼)for the treatment of type 2 diabetes mellitus. Tell me more about glargine + lixisenatide
GREEN CALCIPOTRIOL and BETAMETHASONE cutaneous foam (Enstilar®)
The Pan Mersey Area Prescribing Committee recommends the prescribing of CALCIPOTRIOL 50 micrograms and BETAMETHASONE 500 micrograms per 1 gram cutaneous foam (Enstilar®)for psoriasis vulgaris in adults. Tell me more about Enstilar
Dry eye symptoms, non-specialist management
Issued: June 2017 | Review: June 2020 Tell me more about dry eyes
Malnutrition, managing adults in the community
Issued: June 2017 | Review: June 2020 Tell me more about malnutrition
PSORIATIC ARTHRITIS and PERIPHERAL SPONDYLOARTHROPATHY
Biological agents pathway for Psoriatic Arthritis and Peripheral Spondyloarthropathy
Issued: June 2017 | Review: June 2020 Tell me more about the biologics pathway
Biological agents policy for Psoriatic Arthritis
Issued: June 2017 | Review: June 2020 Tell me more about the biologics policy
|For more information on the updates listed below, please click here:
Brimonidine gel (Mirvaso®): risk of systemic cardiovascular effects;
Warn patients not to apply brimonidine gel to irritated or damaged skin, including after laser therapy to the skin.
Denosumab (Prolia®, Xgeva®▼):
The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving denosumab who present with ear symptoms including chronic ear infections or in those with suspected cholesteatoma.
e-cigarettes and refill containers (e-liquids):
Members of the public and healthcare professionals can use the Yellow Card Scheme website to report any suspected side effects or safety concerns with e-cigarettes and the e-liquids used for vaping.
Influenza Season 2016/17:
Prescribers working in primary care and community pharmacists should no longer prescribe or supply antiviral medicines for the prophylaxis and treatment of influenza on an FP10 prescription form.
Risk minimisation materials: Physician prescribing checklist for Mysimba® (8mg naltrexone /90mg bupropion) prolonged-release tablets;
This checklist ensures the appropriate contraindications and special warnings/precautions are considered when prescribing Mysimba prolonged-release tablets.
Risk management materials for Valdoxan® (agomelatine) – liver function monitoring and drug interactions.
New guidance for healthcare professionals has been provided for monitoring liver function in patients before and during treatment with Valdoxan.
Educational Risk Minimisation Materials: Prescribers’ Administration Guide for Qutenza® (capsaicin)
Covers warnings and precautions for use, practice precautions, briefing the patient, correct application of patch, managing treatment-associated discomfort, and patient follow-up.